Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group-Reference-Cited by-同舟云学术

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Published:2021-02-02 Issue:4 Volume:100 Page:1059-1063
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Vozella Federico^ORCID,Siniscalchi A.,Rizzo M.,Za T.,Antolino G.,Coppetelli U.,Piciocchi A.,Andriani A.,Annibali O.,De Rosa L.,Cimino G.,La Verde G.,De Stefano V.,Cantonetti M.,di Toritto T. Caravita,Petrucci M. T.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-04374-y.pdf

Reference16 articles.

1. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840–1848

2. Overdijk MB, Verploegen S, Bogels M et al (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 7:311–321

3. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Bardeja J, Gharibo M, Stevens DA, Le Blanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:1551–1560

4. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NWCJ, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207–1219

5. Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H (2016) Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 128:37–44

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series;eJHaem;2024-08-06

2. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye;Turkish Journal of Hematology;2023-12-28

3. Putting the best foot forward when treating newly diagnosed multiple myeloma;Internal Medicine Journal;2023-03

4. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results;Frontiers in Oncology;2022-05-11

5. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database;British Journal of Haematology;2022-04-05